Press release


07/11/2017
Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)
SOM Biotech
SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension therapy bevantolol (Calvan®): Huntington's disease.
 
 
 
 
 
Permalink  
 
Developed by Web4Bio